Cargando…

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome

SUMMARY: We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerard, Laura, Barthelemy, David, Gauthier, Arnaud, Hervieu, Valerie, Lopez, Jonathan, Gibert, Benjamin, Lasolle, Helene, Chardon, Laurence, Garcia, Jessica, Raverot, Gérald, Payen, Léa, Walter, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265538/ https://www.ncbi.nlm.nih.gov/pubmed/37435182 http://dx.doi.org/10.1530/EO-21-0012

Ejemplares similares

Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)
por: Garcia, Jessica, et al.
Publicado: (2018)

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers
por: Freis, Patricia, et al.
Publicado: (2017)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

Novel technologies in cfDNA analysis and potential utility in clinic
por: Li, Jie, et al.
Publicado: (2021)

Emerging and Novel Treatments for Pituitary Tumors
por: Ilie, Mirela Diana, et al.
Publicado: (2019)

cfDNA methylome profiling for detection and subtyping of small cell lung cancers
por: Chemi, Francesca, et al.
Publicado: (2022)

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016)

cfDNA screening and diagnosis of monogenic disorders – where are we heading?
por: Chiu, Eunice Ka Long, et al.
Publicado: (2018)

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients
por: Boldrin, Elisa, et al.
Publicado: (2020)

Impact of mosaicism ratio on positive predictive value of cfDNA screening
por: Rafalko, Jill M., et al.
Publicado: (2020)

cfDNA Changes in Maximal Exercises as a Sport Adaptation Predictor
por: Humińska-Lisowska, Kinga, et al.
Publicado: (2021)

Deep cfDNA fragment end profiling enables cancer detection
por: Zhitnyuk, Yulia V., et al.
Publicado: (2022)

Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
por: Sugasawa, Takehito, et al.
Publicado: (2021)

The utility of cfDNA in TGCT patient management: a systematic review
por: Krasic, Jure, et al.
Publicado: (2022)

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer
por: Liang, Leilei, et al.
Publicado: (2022)

cfDNA Methylation Profiles and T-Cell Differentiation in Women with Endometrial Polyps
por: Li, Xiao-Hong, et al.
Publicado: (2022)

Hypertensive disorders of pregnancy share common cfDNA methylation profiles
por: Spinelli, Marialuigia, et al.
Publicado: (2022)

Brave new world of cfDNA-omics for early cancer detection
por: Rolfo, Christian, et al.
Publicado: (2023)

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
por: Medina Diaz, Inga, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors
por: McEwen, Abbye E., et al.
Publicado: (2020)

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
por: Silva, Romina, et al.
Publicado: (2021)

MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data
por: Han, Xinyin, et al.
Publicado: (2021)

Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
por: Barbirou, Mouadh, et al.
Publicado: (2022)

Erratum to “The utility of cfDNA in TGCT patient management: a systematic review”
Publicado: (2022)

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker
por: Škara, Lucija, et al.
Publicado: (2023)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
por: Pokrywka, Andrzej, et al.
Publicado: (2015)

Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

cfDNA and DNases: New Biomarkers of Sepsis in Preterm Neonates—A Pilot Study
por: Lenz, Moritz, et al.
Publicado: (2022)

Bile is a reliable and valuable source to study cfDNA in biliary tract cancers
por: Li, Zhanghui, et al.
Publicado: (2022)

Nosological and Theranostic Approach to Vascular Malformation through cfDNA NGS Liquid Biopsy
por: Serio, Viola Bianca, et al.
Publicado: (2022)

Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
por: Fairley, Jennifer A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kqs1jm4v537b0456q38lune55l